Share Article
- Product Sales of
- Diluted EPS of
- Non-GAAP Diluted EPS of
- Revised Full Year 2018 Guidance for Non-GAAP Effective Tax Rate -
| Three Months Ended | Six Months Ended | ||||||||
| June 30, | June 30, | ||||||||
| (In millions, except per share amounts) | 2018 | 2017 | 2018 | 2017 | |||||
| Product sales | $ | 5,540 | $ | 7,046 | $ | 10,541 | $ | 13,423 | |
| Royalty, contract and other revenues | 108 | 95 | 195 | 223 | |||||
| Total revenues | $ | 5,648 | $ | 7,141 | $ | 10,736 | $ | 13,646 | |
| Net income attributable to Gilead | $ | 1,817 | $ | 3,073 | $ | 3,355 | $ | 5,775 | |
| Non-GAAP net income | $ | 2,494 | $ | 3,372 | $ | 4,452 | $ | 6,321 | |
| Diluted earnings per share | $ | 1.39 | $ | 2.33 | $ | 2.55 | $ | 4.38 | |
| Non-GAAPdiluted earnings per share | $ | 1.91 | $ | 2.56 | $ | 3.39 | $ | 4.79 | |
Product Sales
Total product sales for the second quarter of 2018 were
___________________________________ |
Note: Non-GAAP financial information excludes acquisition-related, up-front collaboration, stock-based compensation and other expenses, fair value adjustments of marketable equity securities and measurement period adjustments relating to the enactment of the 2017 Tax Cuts and Jobs Act (Tax Reform). A reconciliation between GAAP and non-GAAP financial information is provided in the tables on page 8, 9 and 10.
- HIV product sales(1) were
$3.7 billion for the second quarter of 2018 compared to$3.2 billion for the same period in 2017. The increase was primarily due to the continued uptake of products containing emtricitabine (FTC) and tenofovir alafenamide (TAF), which include Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg), Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg). - Chronic hepatitis C (HCV) product sales, which consist of
Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), Harvoni®
(ledipasvir 90 mg/sofosbuvir 400 mg), Vosevi®
(sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) and Sovaldi®
(sofosbuvir 400 mg), were
$1.0 billion for the second quarter of 2018 compared to$2.9 billion for the same period in 2017. The decline was primarily due to lower sales of Harvoni, Epclusa and Sovaldi across all major markets as a result of increased competition. - Yescarta® (axicabtagene ciloleucel), which
was launched in
the United States inOctober 2017 , generated$68 million in sales during the second quarter of 2018. -
Other product sales, which include products from Gilead’s chronic
hepatitis B (HBV), cardiovascular, oncology and other categories
inclusive of Vemlidy® (tenofovir alafenamide), Viread®
(tenofovir disoproxil fumarate), Letairis® (ambrisentan),
Ranexa® (ranolazine), Zydelig® (idelalisib) and
AmBisome® (amphotericin B liposome for injection), were
$807 million for the second quarter of 2018 compared to$932 million for the same period in 2017.
Operating Expenses
| Three Months Ended | Six Months Ended | ||||||||
| June 30, | June 30, | ||||||||
| (In millions) | 2018 | 2017 | 2018 | 2017 | |||||
| Research and development expenses (R&D) | $ | 1,192 | $ | 864 | $ | 2,129 | $ | 1,795 | |
| Non-GAAP R&D expenses | $ | 921 | $ | 812 | $ | 1,735 | $ | 1,701 | |
| Selling, general and administrative expenses (SG&A) | $ | 980 | $ | 897 | $ | 1,977 | $ | 1,747 | |
| Non-GAAP SG&A expenses | $ | 840 | $ | 827 | $ | 1,724 | $ | 1,634 | |
During the second quarter of 2018, compared to the same period in 2017:
-
R&D expenses increased primarily due to up-front collaboration
expenses related to Gilead’s collaboration agreement with
Sangamo Therapeutics, Inc. , expense associated with Gilead’s purchase of aU.S. Food and Drug Administration (FDA ) Priority Review Voucher and stock-based compensation expenses associated with Gilead’s acquisition ofKite Pharma, Inc. (Kite). - Non-GAAP R&D expenses increased primarily due to expense associated with Gilead’s purchase of an FDA Priority Review Voucher.
- SG&A expenses increased primarily due to stock-based compensation expenses associated with Gilead’s acquisition of Kite and higher costs to support the growth of Gilead’s business following the acquisition of Kite.
- Non-GAAP SG&A expenses increased primarily due to higher costs to support the growth of Gilead’s business following the acquisition of Kite.
| ___________________________________ |
(1) Excludes sales of Viread as Viread is primarily used for treatment of chronic hepatitis B (HBV).
Effective Tax Rate
The effective tax rate and non-GAAP effective tax rate in the second quarter of 2018 were 12.8% and 13.4% compared to 24.3% and 22.8% in the first quarter of 2018, respectively. The effective tax rate and non-GAAP effective tax rate were lower in the second quarter of 2018 primarily due to a favorable settlement of a tax examination. For the full year 2018, Gilead has revised its non-GAAP effective tax rate to be in the range of 19.0% - 21.0%.
Gilead is unable to project potential measurement period adjustments during 2018 relating to Tax Reform. As a result, Gilead is unable to project an effective tax rate on a GAAP basis.
Cash,
As of
Revised Full Year 2018 Guidance
Gilead revised its full year 2018 guidance, initially provided on
| (In millions, except percentages and per share amounts) | Initially ProvidedFebruary 6, 2018 Reiterated May 1, 2018 | UpdatedJuly 25, 2018 |
| Net Product Sales | $20,000 - $21,000 | $20,000 - $21,000 |
| Non-GAAP | ||
| Product Gross Margin | 85% - 87% | 85% - 87% |
| R&D Expenses | $3,400 - $3,600 | $3,400 - $3,600 |
| SG&A Expenses | $3,400 - $3,600 | $3,400 - $3,600 |
| Effective Tax Rate | 21.0% - 23.0% | 19.0% - 21.0% |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $1.41 - $1.51 | $1.50 - $1.60 |
Corporate Highlights
-
Announced the promotion of
Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead’s corporate development, alliance management, competitive intelligence and corporate strategy and planning functions.Martin Silverstein , Executive Vice President, Strategy, has decided to leave Gilead at the end of August. - Announced that Harish M. Manwani has been appointed to Gilead’s Board of Directors.
Product and Pipeline Updates announced by Gilead during the Second Quarter of 2018 include:
HIV and Liver Diseases Programs
-
Announced that the
European Commission has granted Marketing Authorization for Biktarvy for the treatment of HIV-1 infection. -
Announced a research collaboration and license agreement with
Hookipa Biotech AG (Hookipa) that grants Gilead exclusive rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization technologies for HBV and HIV. -
Announced that the
China Drug Administration (CDA) has approved Epclusa for the treatment of adults with genotype 1-6 HCV infection. The CDA also approved Epclusa in combination with ribavirin for adults with HCV and decompensated cirrhosis. -
Announced that
FDA has approved Truvada®- in combination with safer sex practices - to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. -
Presented data at The International Liver Congress™ 2018, which
included the announcement of:
- The completion of enrollment, ahead of schedule, of STELLAR-3 and STELLAR-4, two ongoing Phase 3 trials evaluating the apoptosis signal-regulating kinase 1 inhibitor selonsertib in patients with F3 and F4 stages of fibrosis due to nonalcoholic steatohepatitis (NASH).
- Results from a proof-of-concept study of investigational combination therapies for patients with NASH, combining selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor agonist GS-9674. Based on this 12-week study, these combination therapies were well tolerated and offered additional benefits for improving NASH by reducing liver fat content, liver cell injury and fibrosis. Gilead has initiated a larger 350-patient Phase 2b study of combinations of selonsertib, GS-0976 or GS-9674 in patients with advanced fibrosis due to NASH.
- Results from two studies utilizing machine learning techniques which suggest that noninvasive tests perform as effectively as liver biopsy for predicting clinical outcomes in patients with advanced fibrosis due to NASH.
Oncology and Cell Therapy Programs
-
Announced that the European Medicines Agency’s
Committee for Medicinal Products for Human Use has issued a positive opinion on Gilead’s Marketing Authorization Application for Yescarta as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy. -
Presented data at the 2018
American Society of Clinical Oncologists Annual Meeting, which included the announcement of:-
Results from an ongoing Phase 1 study conducted by the
National Cancer Institute showing that clinical responses were observed with investigational T cell receptor cell therapy targeting human papillomavirus (HPV) type 16 E7 in solid tumor cancers caused by HPV. - Analyses of the ZUMA-1 study of Yescarta in adult patients with refractory large B-cell lymphoma showing that response status may predict rates of progression-free survival and that treatment responses were consistent across prior lines of therapy.
- An analysis of the ZUMA-3 study evaluating investigational KTE-C19 for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia showed that patients experienced manageable safety and encouraging efficacy irrespective of prior blinatumomab use.
-
Results from an ongoing Phase 1 study conducted by the
-
Announced new worldwide facilities to advance manufacturing of cell
therapies for people with cancer and a new cooperative research and
development agreement with the
National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens.
Inflammation Programs
-
Announced that the randomized, placebo-controlled Phase 2 EQUATOR
study of filgotinib, an investigational, selective JAK1 inhibitor, in
131 adults with moderate to severe psoriatic arthritis, achieved its
primary endpoint of improvement in the signs and symptoms of psoriatic
arthritis at week 16, as assessed by the
American College of Rheumatology 20 percent improvement score. - Announced that an independent Data Monitoring Committee (DMC) conducted a planned interim futility analysis of the filgotinib Phase 2b/3 ulcerative colitis study, SELECTION, after 350 patients completed the induction period in the Phase 2b portion of the study. The DMC recommended that the study proceed into Phase 3 as planned at both the 100 mg and 200 mg once daily dose level in biologic-experienced and biologic-naïve patients.
-
Announced a scientific collaboration with
Verily Life Sciences LLC (Verily), an Alphabet company, using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
Non-GAAP Financial Information
The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8, 9 and 10.
Conference Call
At
A replay of the webcast will be archived on the company’s website for
one year and a phone replay will be available approximately two hours
following the call through
About
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead’s ability to achieve its
anticipated full year 2018 financial results; Gilead’s ability to
sustain growth in revenues for its antiviral and other programs; the
risk that private and public payers may be reluctant to provide, or
continue to provide, coverage or reimbursement for new products,
including Vosevi, Yescarta, Epclusa, Biktarvy and Vemlidy; austerity
measures in European countries that may increase the amount of discount
required on Gilead’s products; an increase in discounts, chargebacks and
rebates due to ongoing contracts and future negotiations with commercial
and government payers; a larger than anticipated shift in payer mix to
more highly discounted payer segments and geographic regions and
decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead’s earnings; market
share and price erosion caused by the introduction of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment;
and potential amendments to the Affordable Care Act or other government
action that could have the effect of lowering prices or reducing the
number of insured patients; Gilead’s ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by
wholesalers and retailers which may cause fluctuations in Gilead’s
earnings; Gilead’s ability to develop products utilizing Hookipa’s
TheraT and Vaxwave arenavirus vector-based immunization technologies;
Gilead’s ability to utilize Verily’s Immunoscape platform to identify
and better understand certain inflammatory diseases; Gilead’s ability to
successfully manufacture cell therapies at its new worldwide facilities;
Gilead’s ability to submit new drug applications for new product
candidates in the timelines currently anticipated; Gilead’s ability to
receive regulatory approvals in a timely manner or at all, for new and
current products, including Yescarta in the
All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in its business, including the following: GILEAD®,
ATRIPLA® is a registered trademark of
For more information on
| GILEAD SCIENCES, INC. | |||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (in millions, except per share amounts) | |||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Revenues: | |||||||||||||||||
| Product sales | $ | 5,540 | $ | 7,046 | $ | 10,541 | $ | 13,423 | |||||||||
| Royalty, contract and other revenues | 108 | 95 | 195 | 223 | |||||||||||||
| Total revenues | 5,648 | 7,141 | 10,736 | 13,646 | |||||||||||||
| Costs and expenses: | |||||||||||||||||
| Cost of goods sold | 1,196 | 1,126 | 2,197 | 2,083 | |||||||||||||
| Research and development expenses | 1,192 | 864 | 2,129 | 1,795 | |||||||||||||
| Selling, general and administrative expenses | 980 | 897 | 1,977 | 1,747 | |||||||||||||
| Total costs and expenses | 3,368 | 2,887 | 6,303 | 5,625 | |||||||||||||
| Income from operations | 2,280 | 4,254 | 4,433 | 8,021 | |||||||||||||
| Interest expense | (266 | ) | (269 | ) | (556 | ) | (530 | ) | |||||||||
| Other income (expense), net | 72 | 130 | 242 | 241 | |||||||||||||
| Income before provision for income taxes | 2,086 | 4,115 | 4,119 | 7,732 | |||||||||||||
| Provision for income taxes | 267 | 1,046 | 761 | 1,964 | |||||||||||||
| Net income | 1,819 | 3,069 | 3,358 | 5,768 | |||||||||||||
| Net income (loss) attributable to noncontrolling interest | 2 | (4 | ) | 3 | (7 | ) | |||||||||||
| Net income attributable to Gilead | $ | 1,817 | $ | 3,073 | $ | 3,355 | $ | 5,775 | |||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 1.40 | $ | 2.35 | $ | 2.58 | $ | 4.42 | |||||||||
| Shares used in per share calculation - basic | 1,298 | 1,307 | 1,302 | 1,307 | |||||||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 1.39 | $ | 2.33 | $ | 2.55 | $ | 4.38 | |||||||||
| Shares used in per share calculation - diluted | 1,308 | 1,317 | 1,314 | 1,319 | |||||||||||||
| Cash dividends declared per share | $ | 0.57 | $ | 0.52 | $ | 1.14 | $ | 1.04 | |||||||||
| GILEAD SCIENCES, INC. | |||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (in millions, except percentages and per share amounts) | |||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Cost of goods sold reconciliation: | |||||||||||||||||
| GAAP cost of goods sold | $ | 1,196 | $ | 1,126 | $ | 2,197 | $ | 2,083 | |||||||||
| Acquisition-related – amortization of purchased intangibles | (300 | ) | (210 | ) | (601 | ) | (420 | ) | |||||||||
| Stock-based compensation expenses(1) | (21 | ) | (4 | ) | (34 | ) | (8 | ) | |||||||||
| Other(2) | — | (20 | ) | — | (20 | ) | |||||||||||
| Non-GAAP cost of goods sold | $ | 875 | $ | 892 | $ | 1,562 | $ | 1,635 | |||||||||
| Product gross margin reconciliation: | |||||||||||||||||
| GAAP product gross margin | 78.4 | % | 84.0 | % | 79.2 | % | 84.5 | % | |||||||||
| Acquisition-related – amortization of purchased intangibles | 5.4 | % | 3.0 | % | 5.7 | % | 3.1 | % | |||||||||
| Stock-based compensation expenses(1) | 0.4 | % | — | % | 0.3 | % | — | % | |||||||||
| Other(2) | — | % | 0.3 | % | — | % | 0.1 | % | |||||||||
| Non-GAAP product gross margin(4) | 84.2 | % | 87.3 | % | 85.2 | % | 87.8 | % | |||||||||
| Research and development expenses reconciliation: | |||||||||||||||||
| GAAP research and development expenses | $ | 1,192 | $ | 864 | $ | 2,129 | $ | 1,795 | |||||||||
| Up-front collaboration expenses | (160 | ) | — | (160 | ) | — | |||||||||||
| Acquisition-related – other costs | (9 | ) | — | (25 | ) | — | |||||||||||
| Stock-based compensation expenses(1) | (102 | ) | (47 | ) | (205 | ) | (89 | ) | |||||||||
| Other(2) | — | (5 | ) | (4 | ) | (5 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 921 | $ | 812 | $ | 1,735 | $ | 1,701 | |||||||||
| Selling, general and administrative expenses reconciliation: | |||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 980 | $ | 897 | $ | 1,977 | $ | 1,747 | |||||||||
| Acquisition-related – other costs | (9 | ) | — | (15 | ) | — | |||||||||||
| Stock-based compensation expenses(1) | (129 | ) | (51 | ) | (233 | ) | (94 | ) | |||||||||
| Other(2) | (2 | ) | (19 | ) | (5 | ) | (19 | ) | |||||||||
| Non-GAAP selling, general and administrative expenses | $ | 840 | $ | 827 | $ | 1,724 | $ | 1,634 | |||||||||
| Operating margin reconciliation: | |||||||||||||||||
| GAAP operating margin | 40.4 | % | 59.6 | % | 41.3 | % | 58.8 | % | |||||||||
| Up-front collaboration expenses | 2.8 | % | — | % | 1.5 | % | — | % | |||||||||
| Acquisition-related – amortization of purchased intangibles | 5.3 | % | 2.9 | % | 5.6 | % | 3.1 | % | |||||||||
| Acquisition-related – other costs | 0.3 | % | — | % | 0.4 | % | — | % | |||||||||
| Stock-based compensation expenses(1) | 4.5 | % | 1.4 | % | 4.4 | % | 1.4 | % | |||||||||
| Other(2) | — | % | 0.6 | % | 0.1 | % | 0.3 | % | |||||||||
| Non-GAAP operating margin(4) | 53.3 | % | 64.6 | % | 53.2 | % | 63.6 | % | |||||||||
| Other income (expense), net reconciliation: | |||||||||||||||||
| GAAP other income (expense), net | $ | 72 | $ | 130 | $ | 242 | $ | 241 | |||||||||
| Unrealized losses from marketable equity securities(3) | 64 | — | 19 | — | |||||||||||||
| Non-GAAP other income (expense), net | $ | 136 | $ | 130 | $ | 261 | $ | 241 | |||||||||
| Notes: | ||
(1) | Stock-based compensation expenses for the three and six months ended June 30, 2018 include $141 million and $260 million associated with Gilead’s acquisition of Kite, respectively | |
(2) | Amounts represent restructuring, contingent consideration and/or other individually insignificant amounts | |
(3) | Amounts represent fair value adjustments of marketable equity securities recorded in Other income (expense), net, on Gilead’s Condensed Consolidated Statements of Income as a result of the adoption of Accounting Standards Update No. 2016-01 “Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” in 2018 | |
(4) | Amounts may not sum due to rounding | |
| GILEAD SCIENCES, INC. | |||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (in millions, except percentages and per share amounts) | |||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 30, | June 30, | ||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Effective tax rate reconciliation: | |||||||||||||||||
| GAAP effective tax rate | 12.8 | % | 25.4 | % | 18.5 | % | 25.4 | % | |||||||||
| Up-front collaboration expenses | 0.7 | % | — | % | 0.1 | % | — | % | |||||||||
| Acquisition-related – amortization of purchased intangibles | (0.8 | )% | (1.1 | )% | (1.5 | )% | (1.1 | )% | |||||||||
| Acquisition-related – other costs | 0.1 | % | — | % | — | % | — | % | |||||||||
| Stock-based compensation expenses(1) | 0.7 | % | 0.5 | % | 0.5 | % | 0.5 | % | |||||||||
| Unrealized losses from marketable equity securities(3) | (0.4 | )% | — | % | (0.1 | )% | — | % | |||||||||
| Tax Reform adjustments | 0.5 | % | — | % | 0.2 | % | — | % | |||||||||
| Other(2) | — | % | (0.1 | )% | — | % | (0.1 | )% | |||||||||
| Non-GAAP effective tax rate(4) | 13.4 | % | 24.7 | % | 17.8 | % | 24.7 | % | |||||||||
| Net income attributable to Gilead reconciliation: | |||||||||||||||||
| GAAP net income attributable to Gilead | $ | 1,817 | $ | 3,073 | $ | 3,355 | $ | 5,775 | |||||||||
| Up-front collaboration expenses | 125 | — | 125 | — | |||||||||||||
| Acquisition-related – amortization of purchased intangibles | 281 | 202 | 562 | 404 | |||||||||||||
| Acquisition-related – other costs | 14 | — | 32 | — | |||||||||||||
| Stock-based compensation expenses(1) | 202 | 61 | 362 | 106 | |||||||||||||
| Unrealized losses from marketable equity securities(3) | 63 | — | 18 | — | |||||||||||||
| Tax Reform adjustments | (10 | ) | — | (10 | ) | — | |||||||||||
| Other(2) | 2 | 36 | 8 | 36 | |||||||||||||
| Non-GAAP net income attributable to Gilead | $ | 2,494 | $ | 3,372 | $ | 4,452 | $ | 6,321 | |||||||||
| Diluted earnings per share reconciliation: | |||||||||||||||||
| GAAP diluted earnings per share | $ | 1.39 | $ | 2.33 | $ | 2.55 | $ | 4.38 | |||||||||
| Up-front collaboration expenses | 0.10 | — | 0.10 | — | |||||||||||||
| Acquisition-related – amortization of purchased intangibles | 0.21 | 0.15 | 0.43 | 0.31 | |||||||||||||
| Acquisition-related – other costs | 0.01 | — | 0.02 | — | |||||||||||||
| Stock-based compensation expenses(1) | 0.15 | 0.05 | 0.28 | 0.08 | |||||||||||||
| Unrealized losses from marketable equity securities(3) | 0.05 | — | 0.01 | — | |||||||||||||
| Tax Reform adjustments | (0.01 | ) | — | (0.01 | ) | — | |||||||||||
| Other(2) | — | 0.03 | 0.01 | 0.03 | |||||||||||||
| Non-GAAP diluted earnings per share(4) | $ | 1.91 | $ | 2.56 | $ | 3.39 | $ | 4.79 | |||||||||
| Non-GAAP adjustment summary: | |||||||||||||||||
| Cost of goods sold adjustments | $ | 321 | $ | 234 | $ | 635 | $ | 448 | |||||||||
| Research and development expenses adjustments | 271 | 52 | 394 | 94 | |||||||||||||
| Selling, general and administrative expenses adjustments | 140 | 70 | 253 | 113 | |||||||||||||
| Other income (expense), net adjustment | 64 | — | 19 | — | |||||||||||||
| Total non-GAAP adjustments before tax | 796 | 356 | 1,301 | 655 | |||||||||||||
| Income tax effect | (109 | ) | (57 | ) | (194 | ) | (109 | ) | |||||||||
| Tax Reform adjustments | (10 | ) | — | (10 | ) | — | |||||||||||
| Total non-GAAP adjustments after tax | $ | 677 | $ | 299 | $ | 1,097 | $ | 546 | |||||||||
| Notes: | ||
(1) | Stock-based compensation expenses for the three and six months ended June 30, 2018 include $141 million and $260 million associated with Gilead’s acquisition of Kite, respectively | |
(2) | Amounts represent restructuring, contingent consideration and/or other individually insignificant amounts | |
(3) | Amounts represent fair value adjustments of marketable equity securities recorded in Other income (expense), net, on Gilead’s Condensed Consolidated Statements of Income as a result of the adoption of Accounting Standards Update No. 2016-01 “Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” in 2018 | |
(4) | Amounts may not sum due to rounding | |
| GILEAD SCIENCES, INC. | ||||
| RECONCILIATION OF GAAP TO NON-GAAP 2018 FULL YEAR GUIDANCE | ||||
| (unaudited) | ||||
| (in millions, except percentages and per share amounts) | ||||
Initially ProvidedFebruary 6, 2018ReiteratedMay 1, 2018 | UpdatedJuly 25, 2018 | |||
| Projected product gross margin GAAP to non-GAAP reconciliation: | ||||
| GAAP projected product gross margin | 78% - 80% | 78% - 80% | ||
| Acquisition-related expenses | 7% - 7% | 7% - 7% | ||
| Non-GAAP projected product gross margin(1) | 85% - 87% | 85% - 87% | ||
| Projected research and development expenses GAAP to non-GAAP reconciliation: | ||||
| GAAP projected research and development expenses | $3,785 - $4,050 | $3,965 - $4,260 | ||
| Stock-based compensation expenses(2) | (315) - (350) | (365) - (400) | ||
| Acquisition-related expenses / up-front collaboration expenses | (70) - (100) | (200) - (260) | ||
| Non-GAAP projected research and development expenses | $3,400 - $3,600 | $3,400 - $3,600 | ||
| Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation: | ||||
| GAAP projected selling, general and administrative expenses | $3,865 - $4,110 | $3,835 - $4,080 | ||
| Stock-based compensation expenses(2) | (425) - (450) | (395) - (420) | ||
| Acquisition-related – other costs | (40) - (60) | (40) - (60) | ||
| Non-GAAP projected selling, general and administrative expenses | $3,400 - $3,600 | $3,400 - $3,600 | ||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses(3): | ||||
| Stock-based compensation expenses(2) | $0.50 - $0.56 | $0.50 - $0.54 | ||
| Acquisition-related expenses / up-front collaboration expenses | $0.91 - $0.95 | $1.00 - $1.06 | ||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses(3) | $1.41 - $1.51 | $1.50 - $1.60 | ||
| Notes: | ||
| (1) | Stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin | |
| (2) | Includes stock-based compensation expenses associated with Gilead’s acquisition of Kite | |
| (3) | Excludes fair value adjustments of marketable equity securities, as Gilead is unable to project future fair value adjustments, and measurement period adjustments during 2018 relating to Tax Reform. Gilead is unable to project an effective tax rate on a GAAP basis | |
| GILEAD SCIENCES, INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (unaudited) | ||||||
| (in millions) | ||||||
June 30, | December 31, | |||||
| 2018 | 2017 | |||||
| Cash, cash equivalents and marketable securities | $ | 31,656 | $ | 36,694 | ||
| Accounts receivable, net | 3,541 | 3,851 | ||||
| Inventories | 859 | 801 | ||||
| Property, plant and equipment, net | 3,659 | 3,295 | ||||
| Intangible assets, net | 16,496 | 17,100 | ||||
| Goodwill | 4,124 | 4,159 | ||||
| Other assets | 5,020 | 4,383 | ||||
| Total assets | $ | 65,355 | $ | 70,283 | ||
| Current liabilities | $ | 10,912 | $ | 11,635 | ||
| Long-term liabilities | 32,709 | 38,147 | ||||
| Stockholders’ equity(1) | 21,734 | 20,501 | ||||
| Total liabilities and stockholders’ equity | $ | 65,355 | $ | 70,283 | ||
| Note: | ||
| (1) | As of June 30, 2018, there were 1,296 million shares of common stock issued and outstanding | |
| GILEAD SCIENCES, INC. | |||||||||||||
| PRODUCT SALES SUMMARY | |||||||||||||
| (unaudited) | |||||||||||||
| (in millions) | |||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||
| Atripla – U.S. | $ | 274 | $ | 334 | $ | 502 | $ | 650 | |||||
| Atripla – Europe | 39 | 86 | 90 | 180 | |||||||||
| Atripla – Other International | 36 | 55 | 71 | 97 | |||||||||
| 349 | 475 | 663 | 927 | ||||||||||
| Biktarvy – U.S. | 183 | — | 218 | — | |||||||||
| Biktarvy – Europe | 2 | — | 2 | — | |||||||||
| Biktarvy – Other International | — | — | — | — | |||||||||
| 185 | — | 220 | — | ||||||||||
| Complera / Eviplera – U.S. | 82 | 112 | 149 | 224 | |||||||||
| Complera / Eviplera – Europe | 103 | 127 | 212 | 252 | |||||||||
| Complera / Eviplera – Other International | 14 | 15 | 28 | 31 | |||||||||
| 199 | 254 | 389 | 507 | ||||||||||
| Descovy – U.S. | 311 | 232 | 585 | 441 | |||||||||
| Descovy – Europe | 78 | 47 | 153 | 84 | |||||||||
| Descovy – Other International | 14 | 7 | 26 | 12 | |||||||||
| 403 | 286 | 764 | 537 | ||||||||||
| Genvoya – U.S. | 904 | 710 | 1,757 | 1,379 | |||||||||
| Genvoya – Europe | 207 | 125 | 393 | 212 | |||||||||
| Genvoya – Other International | 49 | 22 | 92 | 35 | |||||||||
| 1,160 | 857 | 2,242 | 1,626 | ||||||||||
| Odefsey – U.S. | 303 | 230 | 582 | 433 | |||||||||
| Odefsey – Europe | 77 | 27 | 135 | 50 | |||||||||
| Odefsey – Other International | 5 | 1 | 10 | 2 | |||||||||
| 385 | 258 | 727 | 485 | ||||||||||
| Stribild – U.S. | 144 | 225 | 277 | 451 | |||||||||
| Stribild – Europe | 34 | 54 | 63 | 121 | |||||||||
| Stribild – Other International | 9 | 14 | 21 | 30 | |||||||||
| 187 | 293 | 361 | 602 | ||||||||||
| Truvada – U.S. | 649 | 567 | 1,156 | 1,031 | |||||||||
| Truvada – Europe | 86 | 184 | 183 | 373 | |||||||||
| Truvada – Other International | 30 | 61 | 78 | 122 | |||||||||
| 765 | 812 | 1,417 | 1,526 | ||||||||||
| Other HIV(1) – U.S. | 11 | 7 | 20 | 21 | |||||||||
| Other HIV(1) – Europe | 3 | 2 | 4 | 3 | |||||||||
| Other HIV(1) – Other International | 5 | 2 | 8 | 2 | |||||||||
| 19 | 11 | 32 | 26 | ||||||||||
| Revenue share – Symtuza – Europe(2) | 13 | — | 20 | — | |||||||||
| Total HIV – U.S. | 2,861 | 2,417 | 5,246 | 4,630 | |||||||||
| Total HIV – Europe | 642 | 652 | 1,255 | 1,275 | |||||||||
| Total HIV – Other International | 162 | 177 | 334 | 331 | |||||||||
| 3,665 | 3,246 | 6,835 | 6,236 | ||||||||||
| GILEAD SCIENCES, INC. | |||||||||||||
| PRODUCT SALES SUMMARY - (Continued) | |||||||||||||
| (unaudited) | |||||||||||||
| (in millions) | |||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||
| AmBisome – U.S. | $ | 14 | $ | 8 | $ | 31 | $ | 17 | |||||
| AmBisome – Europe | 55 | 50 | 111 | 102 | |||||||||
| AmBisome – Other International | 34 | 34 | 68 | 65 | |||||||||
| 103 | 92 | 210 | 184 | ||||||||||
| Epclusa – U.S. | 239 | 864 | 508 | 1,599 | |||||||||
| Epclusa – Europe | 168 | 248 | 366 | 386 | |||||||||
| Epclusa – Other International | 93 | 59 | 162 | 78 | |||||||||
| 500 | 1,171 | 1,036 | 2,063 | ||||||||||
| Harvoni – U.S. | 230 | 984 | 464 | 1,910 | |||||||||
| Harvoni – Europe | 22 | 230 | 78 | 473 | |||||||||
| Harvoni – Other International | 79 | 168 | 137 | 370 | |||||||||
| 331 | 1,382 | 679 | 2,753 | ||||||||||
| Letairis – U.S. | 244 | 230 | 448 | 441 | |||||||||
| Ranexa – U.S. | 208 | 200 | 403 | 353 | |||||||||
| Vemlidy – U.S. | 59 | 21 | 106 | 32 | |||||||||
| Vemlidy – Europe | 3 | 1 | 6 | 1 | |||||||||
| Vemlidy – Other International | 14 | — | 22 | — | |||||||||
| 76 | 22 | 134 | 33 | ||||||||||
| Viread – U.S. | 16 | 141 | 23 | 258 | |||||||||
| Viread – Europe | 32 | 76 | 62 | 147 | |||||||||
| Viread – Other International | 34 | 83 | 94 | 155 | |||||||||
| 82 | 300 | 179 | 560 | ||||||||||
| Vosevi – U.S. | 86 | — | 172 | — | |||||||||
| Vosevi – Europe | 20 | — | 36 | — | |||||||||
| Vosevi – Other International | 3 | — | 8 | — | |||||||||
| 109 | — | 216 | — | ||||||||||
| Yescarta – U.S. | 68 | — | 108 | — | |||||||||
| Zydelig – U.S. | 17 | 19 | 31 | 34 | |||||||||
| Zydelig – Europe | 22 | 16 | 40 | 35 | |||||||||
| Zydelig – Other International | — | — | 1 | 1 | |||||||||
| 39 | 35 | 72 | 70 | ||||||||||
| Other(3) – U.S. | 27 | 98 | 56 | 158 | |||||||||
| Other(3) – Europe | 41 | 126 | 56 | 246 | |||||||||
| Other(3) – Other International | 47 | 144 | 109 | 326 | |||||||||
| 115 | 368 | 221 | 730 | ||||||||||
| Total product sales – U.S. | 4,069 | 4,982 | 7,596 | 9,432 | |||||||||
| Total product sales – Europe | 1,005 | 1,399 | 2,010 | 2,665 | |||||||||
| Total product sales – Other International | 466 | 665 | 935 | 1,326 | |||||||||
| $ | 5,540 | $ | 7,046 | $ | 10,541 | $ | 13,423 | ||||||
| Notes: | ||
| (1) | Includes Emtriva and Tybost | |
| (2) | Represents Gilead’s revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen | |
| (3) | Includes Cayston, Hepsera and Sovaldi | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20180725005788/en/
Source:
Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Sung Lee, 650-524-7792orMediaAmy Flood, 650-522-5643
Other News
Some of the content on this page is not intended for users outside the U.S.